Bayer receives MHRA authorisation for elinzanetant for the treatment of moderate to severe vasomotor symptoms caused by adjuvant endocrine therapy related to breast cancer in women 

For UK Pharma, Medical and Healthcare Media 

• Transparency
• Women's Health